Sun Pharma Advanced Research Company Limited has informed the Exchange about PDP-716 NDA Update
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma Advanced Research Company's licensing partner Ocuvex Therapeutics Inc. has received a Complete Response Letter (CRL) from the US FDA for the PDP-716 New Drug Application. The CRL was issued because of inspection findings at the finished product manufacturing facility. The FDA has not raised any other concerns with the PDP-716 NDA itself, suggesting the drug candidate may still be viable pending resolution of manufacturing issues.
This is a setback for PDP-716's approval timeline as manufacturing inspection deficiencies must be addressed before FDA can approve the NDA. The stock may face negative sentiment in the short term.